AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. The company maintains a confident outlook ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Merck KGaA, Pfizer and Sanofi were among more than 40 international business leaders who met with Xi in ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

Thrombosis incidence in ANNEXA-I was 14.6% for andexanet vs. 6.9% for usual care. ANNEXA-I showed a 65.7% improvement in hemostasis for andexanet vs. 53% for usual care. The market’s back, and ...